278 related articles for article (PubMed ID: 30920339)
1. Combining CDP-choline and galantamine: Effects of a selective α7 nicotinic acetylcholine receptor agonist strategy on P50 sensory gating of speech sounds in healthy volunteers.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
J Psychopharmacol; 2019 Jun; 33(6):688-699. PubMed ID: 30920339
[TBL] [Abstract][Full Text] [Related]
2. Combining CDP-choline and galantamine, an optimized α7 nicotinic strategy, to ameliorate sensory gating to speech stimuli in schizophrenia.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
Int J Psychophysiol; 2019 Nov; 145():70-82. PubMed ID: 30790597
[TBL] [Abstract][Full Text] [Related]
3. CDP-choline and galantamine, a personalized α7 nicotinic acetylcholine receptor targeted treatment for the modulation of speech MMN indexed deviance detection in healthy volunteers: a pilot study.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Illivitsky V; Knott V
Psychopharmacology (Berl); 2020 Dec; 237(12):3665-3687. PubMed ID: 32851421
[TBL] [Abstract][Full Text] [Related]
4. An α7 nAChR approach for the baseline-dependent modulation of deviance detection in schizophrenia: A pilot study assessing the combined effect of CDP-choline and galantamine.
Choueiry J; Blais CM; Shah D; Smith D; Fisher D; Labelle A; Knott V
J Psychopharmacol; 2023 Apr; 37(4):381-395. PubMed ID: 36927273
[TBL] [Abstract][Full Text] [Related]
5. CDP-choline: effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression.
Knott V; Smith D; de la Salle S; Impey D; Choueiry J; Beaudry E; Smith M; Saghir S; Ilivitsky V; Labelle A
J Psychopharmacol; 2014 Dec; 28(12):1095-108. PubMed ID: 25315828
[TBL] [Abstract][Full Text] [Related]
6. Assessing the acute effects of CDP-choline on sensory gating in schizophrenia: A pilot study.
Aidelbaum R; Labelle A; Baddeley A; Knott V
J Psychopharmacol; 2018 May; 32(5):541-551. PubMed ID: 29338621
[TBL] [Abstract][Full Text] [Related]
7. First administration of cytidine diphosphocholine and galantamine in schizophrenia: a sustained alpha7 nicotinic agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Rosse RB; Mastropaolo J; Gaskins B
Clin Neuropharmacol; 2008; 31(1):34-9. PubMed ID: 18303489
[TBL] [Abstract][Full Text] [Related]
8. Targeting alpha-7 nicotinic neurotransmission in schizophrenia: a novel agonist strategy.
Deutsch SI; Schwartz BL; Schooler NR; Brown CH; Rosse RB; Rosse SM
Schizophr Res; 2013 Aug; 148(1-3):138-44. PubMed ID: 23768813
[TBL] [Abstract][Full Text] [Related]
9. Effects of CDP-choline and the combination of CDP-choline and galantamine differ in an animal model of schizophrenia: development of a selective alpha7 nicotinic acetylcholine receptor agonist strategy.
Deutsch SI; Rosse RB; Schwartz BL; Schooler NR; Gaskins BL; Long KD; Mastropaolo J
Eur Neuropsychopharmacol; 2008 Feb; 18(2):147-51. PubMed ID: 17656074
[TBL] [Abstract][Full Text] [Related]
10. Short-term tropisetron treatment and cognitive and P50 auditory gating deficits in schizophrenia.
Zhang XY; Liu L; Liu S; Hong X; Chen DC; Xiu MH; Yang FD; Zhang Z; Zhang X; Kosten TA; Kosten TR
Am J Psychiatry; 2012 Sep; 169(9):974-81. PubMed ID: 22952075
[TBL] [Abstract][Full Text] [Related]
11. Allosteric alpha-7 nicotinic receptor modulation and P50 sensory gating in schizophrenia: a proof-of-mechanism study.
Winterer G; Gallinat J; Brinkmeyer J; Musso F; Kornhuber J; Thuerauf N; Rujescu D; Favis R; Sun Y; Franc MA; Ouwerkerk-Mahadevan S; Janssens L; Timmers M; Streffer JR
Neuropharmacology; 2013 Jan; 64():197-204. PubMed ID: 22766391
[TBL] [Abstract][Full Text] [Related]
12. Baseline dependency of nicotine's sensory gating actions: similarities and differences in low, medium and high P50 suppressors.
Knott V; de la Salle S; Smith D; Phillipe T; Dort H; Choueiry J; Impey D
J Psychopharmacol; 2013 Sep; 27(9):790-800. PubMed ID: 23744798
[TBL] [Abstract][Full Text] [Related]
13. Targeting of α7 Nicotinic Acetylcholine Receptors in the Treatment of Schizophrenia and the Use of Auditory Sensory Gating as a Translational Biomarker.
Hashimoto K
Curr Pharm Des; 2015; 21(26):3797-806. PubMed ID: 26044974
[TBL] [Abstract][Full Text] [Related]
14. Stimulation of nicotinic acetylcholine alpha7 receptors rescue schizophrenia-like cognitive impairments in rats.
Potasiewicz A; Nikiforuk A; Hołuj M; Popik P
J Psychopharmacol; 2017 Feb; 31(2):260-271. PubMed ID: 28168926
[TBL] [Abstract][Full Text] [Related]
15. The acute dose and baseline amplitude-dependent effects of CDP-choline on deviance detection (MMN) in chronic schizophrenia: A pilot study.
Aidelbaum R; Labelle A; Choueiry J; Knott V
Exp Clin Psychopharmacol; 2022 Apr; 30(2):235-248. PubMed ID: 33630646
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of JWX-A0108 as a novel type I positive allosteric modulator of α7 nAChR that can reverse acoustic gating deficits in a mouse prepulse inhibition model.
Sun LL; Yang TY; Wei NN; Lu W; Jiao WX; Zhou QQ; Miao YZ; Gao Q; Wang XT; Sun Q; Wang K
Acta Pharmacol Sin; 2019 Jun; 40(6):737-745. PubMed ID: 30333556
[TBL] [Abstract][Full Text] [Related]
17. Schizophrenia and the alpha7 nicotinic acetylcholine receptor.
Martin LF; Freedman R
Int Rev Neurobiol; 2007; 78():225-46. PubMed ID: 17349863
[TBL] [Abstract][Full Text] [Related]
18. The therapeutic potential of α7 nicotinic acetylcholine receptor (α7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia.
Beinat C; Banister SD; Herrera M; Law V; Kassiou M
CNS Drugs; 2015 Jul; 29(7):529-42. PubMed ID: 26242477
[TBL] [Abstract][Full Text] [Related]
19. α7 nicotinic acetylcholine receptor as a potential therapeutic target for schizophrenia.
Ishikawa M; Hashimoto K
Curr Pharm Des; 2011; 17(2):121-9. PubMed ID: 21355839
[TBL] [Abstract][Full Text] [Related]
20. Neurocognitive effects of acute choline supplementation in low, medium and high performer healthy volunteers.
Knott V; de la Salle S; Choueiry J; Impey D; Smith D; Smith M; Beaudry E; Saghir S; Ilivitsky V; Labelle A
Pharmacol Biochem Behav; 2015 Apr; 131():119-29. PubMed ID: 25681529
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
